



BILL & MELINDA  
GATES foundation

# THE IMPORTANCE OF PARTNERSHIP AND DELIVERY-FOCUSED INNOVATION IN GLOBAL HEALTH

DCVMN Annual Meeting  
October 7, 2013

DR. TREVOR MUNDEL  
PRESIDENT, GLOBAL HEALTH





EVERY PERSON  
DESERVES A CHANCE  
TO LIVE A HEALTHY,  
PRODUCTIVE LIFE.

# OUR PROGRAMS

GLOBAL HEALTH



GLOBAL DEVELOPMENT



UNITED STATES PROGRAM




# OUR GLOBAL REACH AND PRESENCE




# WHAT IS INNOVATION IN GLOBAL HEALTH?

---



**MANUFACTURERS**  
supplying GAVI-funded vaccines  
**DOUBLED**



> TWO THIRDS

of children worldwide get vaccines from DCVMs




>50%

of GAVI's vaccine  
suppliers are DCVMs




**ADDITIONAL CHILDREN IMMUNIZED**  
with GAVI support: **370M**






**36% DROP IN COST** to fully immunize a child with pentavalent, pneumococcal, and rotavirus vaccines.


**In 2009**  
rotavirus  
vaccines were  
**\$7.50**  
per dose.



**In 2012**  
rotavirus vaccines  
dropped to  
**\$2.50**  
per dose.



**In 2015**  
rotavirus vaccines  
will drop to  
**\$1.00**  
per dose.






# ■ PROGRESS IN GLOBAL HEALTH

## Under-Five Child Deaths Worldwide

1960-2012 (in millions)




Source: UNICEF

# WHY INNOVATION IN GLOBAL HEALTH MATTERS

Significant under-5 child mortality could be prevented with existing interventions


## Major preventable causes of under-5 child deaths from infectious diseases (2011)



# COMMUNICABLE, MATERNAL, NEONATAL AND NUTRITIONAL DISORDERS





1990



2010



Latin America and Caribbean, DALYs - *both sexes, all ages*




Sub-Saharan Africa, DALYs - *both sexes, all ages*

HOW DO WE ACHIEVE  
THE GREATEST IMPACT  
WITH INVESTMENT  
DOLLARS?

# GUIDING OUR INVESTMENTS IN GLOBAL HEALTH



Bubble size is  
equivalent to  
the amount of  
DALYs averted






# GUIDING OUR INVESTMENTS IN GLOBAL HEALTH


■ HIV/AIDS  
■ Malaria  
■ TB  
■ Pneumonia  
■ EDD  
■ NID

Bubble size is equivalent to the amount of DALYs averted


100M DALYs Averted



# GUIDING OUR INVESTMENTS IN GLOBAL HEALTH



Bubble size is equivalent to the amount of DALYs averted



# OUR PARTNERS



# OUR PARTNERS



# GLOBAL HEALTH INVESTMENT FUND


- An innovative approach to funding promising global health technologies
- A social impact fund open to individual and institutional investors
- Focused on development of drugs, vaccines, diagnostics, and other interventions for low-income countries
- New technologies will target malaria, TB, HIV/AIDS, and maternal and infant mortality





## PROGRAM-RELATED INVESTMENTS

High-impact tools to stimulate private-sector innovation, encourage market-driven efficiencies, and attract external capital to priority initiatives



## THE MENINGITIS VACCINE PROJECT

- A mid-1990s meningitis epidemic in Africa caused 25,000 deaths and left thousands more with permanent disabilities
- African leaders asked for help developing an effective, low-cost vaccine to stem the disease
- An innovative global partnership led to development of the MenAfriVac<sup>®</sup> vaccine at US\$.50/dose
- Introduction strategy included mass vaccination for immediate benefit and integration into routine childhood immunization programs




# THE MENINGITIS VACCINE PROJECT

- An innovative, global partnership to end deadly Men A epidemics in Africa
- Rapid development and low cost – US\$.50 a dose – were key
- A two-fold introduction strategy:
  - Mass vaccination to gain immediate benefits
  - Integration into routine childhood immunization programs

## Our Partners



# MENAFRIVAC: AFRICAN MENINGITIS BELT



# OUR COMMITMENT TO DCVMs – PARTNERSHIPS AND TECHNOLOGIES

- Enabling strong partnerships with MNCs and PDPs has led to breakthrough pricing innovations and enhanced supply security
- We are scanning the world for innovations in vaccine development to share with DCVMs
  - New conjugation technologies
  - New adjuvant technologies
  - Process development advances






# OUR COMMITMENT TO DCVMs – REGULATORY AND QUALITY

- Working with partners in India and China, help increase the number of submissions of high-quality dossiers for WHO
  - By providing scientific, technical, and regulatory advice to manufacturers to minimize regulatory delay and speed access to needed products
  - By improving incentives for PQ application in order to enhance supply security for critical vaccines



# UNMET NEEDS TO BE ADDRESSED BY DCVMs

- Low-cost vaccines with the following attributes:
  - Single-dose
  - Thermostable
  - Efficacious in children with compromised gastrointestinal tracts
- New vaccines required to meet the health challenges of the next generation, as it will take decades to fill existing infrastructural gaps
  - Partner on new financial models to develop vaccines





A large group of children, mostly of South Asian descent, are gathered together in a dirt area. They are wearing various types of clothing, including sweaters, hoodies, and head coverings like scarves and beanies. The children are looking in different directions, some towards the camera, some away. The background is a simple, dusty ground.

# THE TECHNOLOGY CHALLENGE IN THE DEVELOPING WORLD



EVERY PERSON  
DESERVES THE  
CHANCE TO LIVE  
A HEALTHY,  
PRODUCTIVE LIFE

BILL & MELINDA  
GATES Foundation  
VISITOR CENTER

ENTRANCE  
CURRICULUM